Schmerztherapie mit traditionellen NSAR und Coxiben – eine interdisziplinäre Betrachtung

Schlüsselwörter

Schmerztherapie - nichtsteroidale Antirheumatika - NSAR - Coxibe

Keywords

pain treatment - non steroidal antirheumatic drugs - NSAIDs - coxibs

• Literatur

• 1 Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
• 2 Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum 2003; 48: 12-20
• 3 Breivik H, Collett B, Ventafridda V et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333
• 4 Chan F, Lana A, Scheiman J et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-179
• 5 Chan F, Wong VWS, Suen BY et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621-1626
• 6 Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238-244
• 7 Chan C, Reid C, Aw T. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27: 2332-2341
• 8 Combe B et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs. diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 2009; 48: 425-432
• 9 Dougados M, Behier JM, Jolchine I et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44: 180-185
• 10 Emery P, Zeidler H, Kvien TK et al. Celecoxib versus Diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999; 354: 2106-2111
• 11 Fischbach W, Darius H, Gross M et al. Positionspapier der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Kardiologie (DGK). Z Gastroenterol 2010; 48: 1-8
• 12 Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-Leitlinie „Helicobacter pylori und gastroduodenale Ulkuskrankheit“ der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). In Zusammenarbeit mit der Deutschen Gesellschaft für Hygiene und Mikrobiologie, Gesellschaft für Pädiatrische Gastroenterologie und Ernährung e.V. und der Deutschen Gesellschaft für Rheumatologie – AWMF-Register-Nr. 021/001. Z Gastroenterol 2009; 47: 68-102
• 13 FitzGerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-442
• 14 Goldstein JL, Eisen GM, Lewis B et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007; 25: 1211-1222
• 15 Goldstein JL, Johanson JF, Hawkey CJ et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther 2007; 26: 1101-1111
• 16 Gyllfors P, Bochenek G, Overholt J et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003; 111: 1116-1121
• 17 Helin-Salmivaara A, Huttunen T, Gronroos JM et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. Eur J Clin Pharmacol 2007; 63: 403-408
• 18 Hernandez-Dıaz S, Varas-Lorenzo C, Rodrıguez L. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol 2006; 98: 266-274
• 19 Hinz B, Renner B, Brune K. Drug insight: cyclo-oxygenase-2 inhibitors. A critical appraisal. Nat Clin Pract Rheumatol 2007; 3: 552-560
• 20 Hunt RH, Lanas A, Stichtenoth DO et al. Myths and facts in the use of anti-inflammatory drugs. Ann Med 2009; 41: 423-437
• 21 Laine L, Curtis SP, Langman M et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008; 135: 1517-1525
• 22 Laine L, Smith R, Min K et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006; 24: 751-767
• 23 Lanas A, Tornero J, Zamorano JL. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010; 69: 1453-1458
• 24 Moore RA, Derry S, McQuay H. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskeletal Disorders 2007; 8: 73 doi: DOI: 10.1186/1471-2474-8-73.
• 25 Moskowitz RW, Sunshine A, Brugger A et al. American pain society pain questionnaire and other pain measures in the assessment of osteoarthritis pain: a pooled analysis of three celecoxib pivotal studies. Am J Ther 2003; 10: 12-20
• 26 Rostom A, Muir K, Dube C et al. Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5: 818-828.e5
• 27 Sawitzke AD, Shi H, Finco MF et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010; 69: 1459-1464
• 28 Schaible HG. Epidemiology and pathophysiology of pain – new targets for pain therapy. Med Monatsschr Pharm 2009; 32: 164-171
• 29 Sieper J, Klopsch T, Richter M et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis. Ann Rheum Dis 2008; 67: 323-329
• 30 Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999; 282: 1921-1928
• 31 Singh G, Fort JG, Goldstein JL et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006; 119: 255-266
• 32 Spiegel BMR, Farid M, Dulai GS et al. Comparing rates of dyspepsia with coxibs vs NSAID + PPI. Am J Med 2006; 119: 448.e27-e36
• 33 Stichtenoth DO, Frölich JC. COX 2 and the kidneys. Curr Pharm Des 2000; 6: 1737-1753
• 34 Stichtenoth DO. Medikamentöse Therapie mit nichtsteroidalen Antirheumatika. In: Pro-CME. 4.. Aufl, Stuttgart: Thieme; 2011
• 35 Stichtenoth DO. The second generation of COX 2 inhibitors: clinical pharmacological point of view. Mini Rev Med Chem 2004; 4: 617-624
• 36 Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ Publishing Group; 2011
• 37 Vane JR. Towards a better aspirin. Nature 1994; 367: 215 - 216
• 38 Wanders A, Heijde D, Landewe R et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum 2005; 52: 1756-1765
• 39 White W, West C, Borer J et al. Risk of cardiovascular events in patients receiving celecoxib. Am J Cardiol 2007; 99: 91-98
• 40 Zhao SZ, Fiechtner JI, Tindall EA et al. Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib. Arthritis Care Res 2000; 13: 112-121
• 41 Zhao SZ, McMillen JI, Markenson JA et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999; 19: 1269-1278